Healthcare - Biotechnology - NASDAQ - US
$ 1.36
-6.85 %
$ 6.09 M
Market Cap
-0.01
P/E
Price Target
Average
--100.00%
Revenue Forecast
Estimate
-0.00%
EBIT
Estimate
18.92%
Net Income
Estimate
31.00%
WALL STREET ESTIMATES
Wall Street Analysts Price Targets
Alzamend Neuro, Inc.
ALZN has no price targets from Wall Street.
REVENUE FORECAST
Revenue Forecast Chart ALZN
EBIT FORECAST
EBIT Forecast Chart ALZN
NET INCOME FORECAST
Net Income Chart ALZN